

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

FURTHER EXTENSION OF LONG STOP DATE OF THE CONNECTED TRANSACTION INVOLVING ALLOTMENT AND ISSUE OF NEW SHARES UNDER SPECIFIC MANDATE

Reference is made to the announcements of Sinopharm Tech Holdings Limited (the “**Company**”) dated 2 April 2020, 16 June 2020, 31 July 2020 and 28 August 2020 (the “**Announcements**”) in relation to the entering into of the Subscription Agreement, the supplemental agreement, the second supplemental agreement and the third supplemental agreement and the Subscription thereunder, which constituted a connected transaction of the Company under Chapter 20 of the GEM Listing Rules. Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

FURTHER EXTENSION OF THE LONG STOP DATE

Pursuant to the Subscription Agreement, the Completion is conditional upon and subject to all the conditions precedent being fulfilled or waived on or before 30 June 2020 (the “**Long Stop Date**”). On 16 June 2020, the parties to the Subscription Agreement entered into the supplemental agreement to extend the Long Stop Date to 31 July 2020 (or such later date as the parties may agree in writing). On 31 July 2020, the parties to the Subscription Agreement entered into the second supplemental agreement to further extend the Long Stop Date to 28 August 2020 (or such later date as the parties may agree in writing). On 28 August 2020, the parties to the Subscription Agreement entered into the third supplemental agreement to further extend the Long Stop Date to 30 September 2020 (or such later date as the parties may agree in writing). On 30 September 2020, the parties to the Subscription Agreement entered into the fourth supplemental agreement to further extend the Long Stop Date to 31 October 2020 (or such

later date as the parties may agree in writing). Save as aforesaid, all other terms and conditions of the Subscription Agreement shall remain unchanged.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Executive Director and Chief Executive Officer

Hong Kong, 5 October 2020

As at the date of this announcement, the Board comprises Madam CHEUNG Kwai Lan, Mr. CHAN Ting as executive Directors, Mr. CHAN Tung Mei and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.